Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease

被引：1

作者：

Yoshimoto, Masatoshi ^{[1
]}

Sekine, Akinari ^{[1
,2
]}

Suwabe, Tatsuya ^{[1
,2
]}

Oba, Yuki ^{[1
]}

Mizuno, Hiroki ^{[1
]}

Yamanouchi, Masayuki ^{[1
,2
]}

Ubara, Yoshifumi ^{[1
]}

Hoshino, Junichi ^{[1
,3
]}

Inoue, Noriko ^{[1
]}

Tanaka, Kiho ^{[1
]}

Hasegawa, Eiko ^{[1
]}

Sawa, Naoki ^{[1
,2
]}

Wada, Takehiko ^{[1
,2
]}

机构：

[1] Toranomon Gen Hosp, Nephrol Ctr, Tokyo, Japan

[2] Okinaka Mem Inst Med Res, Tokyo, Japan

[3] Tokyo Womens Med Univ, Dept Nephrol, Tokyo, Japan

来源：

CLINICAL KIDNEY JOURNAL | 2024年 / 17卷 / 08期

关键词：

ADPKD; CKD; dapagliflozin; eGFR slope; total kidney volume; GLUCOSE COTRANSPORTER 2; INHIBITION; CRITERIA;

D O I：

10.1093/ckj/sfae186

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction The DAPA-CKD study showed a protective effect of dapagliflozin on kidney function in chronic kidney disease (CKD) patients with and without diabetes mellitus. Although dapagliflozin is expected to be effective also in CKD patients with autosomal dominant polycystic kidney disease (ADPKD), its efficacy and safety in this population remain unknown because ADPKD was an exclusion criterion in the DAPA-CKD study. Therefore, we evaluated the effects of dapagliflozin in CKD patients with ADPKD.Methods We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before and after starting dapagliflozin treatment.Results The median observation period after starting dapagliflozin was 20 months. Four patients received concomitant tolvaptan. The eGFR slope before and after initiation of dapagliflozin could be calculated in six patients and improved in all of them except the one who did not receive a renin-angiotensin system (RAS) inhibitor. Annual height-corrected total kidney volume increased in all patients. Concurrent tolvaptan treatment had no effect.Conclusion In CKD patients with ADPKD, dapagliflozin may increase kidney volume but may have a protective effect on kidney function when used concomitantly with RAS inhibitors.

引用

页数：6

共 50 条

[11] Autosomal dominant polycystic kidney disease
Silverman, Jonathan
Desai, Chaitanya
Lerma, Edgar V.
DM DISEASE-A-MONTH, 2015, 61 (10): : 442 - 447
[12] Autosomal dominant polycystic kidney disease
Cornec-Le Gall, Emilie
Alam, Ahsan
Perrone, Ronald D.
LANCET, 2019, 393 (10174): : 919 - 935
[13] Autosomal dominant polycystic kidney disease
Pirson, Y
Chauveau, D
Watson, ML
Zeier, M
Breuning, MH
M S-MEDECINE SCIENCES, 1997, 13 (01): : 37 - 44
[14] Autosomal dominant polycystic kidney disease
Beebe, DK
AMERICAN FAMILY PHYSICIAN, 1996, 53 (03) : 925 - 931
[15] Autosomal dominant polycystic kidney disease
Torres, Vicente E.
Harris, Peter C.
Pirson, Yves
LANCET, 2007, 369 (9569): : 1287 - 1301
[16] AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE
Pljesa, Steva
SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2008, 136 : 340 - 347
[17] Autosomal dominant polycystic kidney disease
Ferrer, Elisa
Bozzo, Jordi
DRUGS OF THE FUTURE, 2006, 31 (07) : 611 - 615
[18] Autosomal Dominant Polycystic Kidney Disease
Perumareddi, Parvathi
Trelka, Darin P.
PRIMARY CARE, 2020, 47 (04): : 673 - 689
[19] Autosomal Dominant Polycystic Kidney Disease
Suarez, Maria Lourdes Gonzalez
Titan, Silvia
Dahl, Neera K.
ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (06): : 496 - 503
[20] Autosomal dominant polycystic kidney disease: Is the treatment for tomorrow?
Cornec-Le Gall, Emilie
Le Meur, Yannick
NEPHROLOGIE & THERAPEUTIQUE, 2014, 10 (06): : 433 - 440

← 1 2 3 4 5 →